SER
SER (the “Company”), a leading global Intelligent Content Automation (“ICA”) software vendor in the Enterprise Content Management (“ECM”) market, today announced that TA Associates (“TA”), a leading global private equity firm, has agreed to make a strategic growth investment in the Company. SER and Carlyle, an investor in SER since 2018, welcome TA as the new lead investor.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321414321/en/
“We are delighted to welcome TA to SER as an investor and we are proud that they share our perspective on the significant opportunities ahead for our business,” said Dr. John Bates, CEO of SER. “SER is revolutionizing the way enterprise content is automated, understood and managed. We have amazing customers, a fantastic team and market leading technology. We have had an outstanding partnership with Carlyle, with incredible support throughout the journey, and we are delighted that TA now joins us to supercharge the next phase of growth.”
Since its founding in 1984, SER has developed from a primarily DACH-focused ECM solutions provider into a category-defining ICA player with highly differentiated AI capabilities and an increasingly international enterprise customer base. In partnership with Carlyle, SER built out its senior management team, successfully executed a rapid shift to a subscription-first business model, expanded its innovation-led product offering, and entered new markets including the US, UK, continental Europe, and the Middle East, through considerable organic investment and M&A.
Today, SER has over 600 employees across 20 offices in 11 countries. The Company’s technology is trusted by blue-chip enterprise customers worldwide. SER’s flagship product, Doxis ICA (“Doxis”), combines traditional ECM capabilities with AI-enabled services that are designed to bridge and automate content across best-of-breed apps and multiple vendor ecosystems like SAP, Salesforce, Microsoft and more.
“SER’s impressive suite of next-generation ECM solutions helps organizations work faster, smarter and more efficiently,” said Morgan Seigler, Managing Director at TA, and Stefan Dandl, Director at TA. “As the demand for AI-powered technologies continues, we believe SER has a meaningful opportunity to support organizations in their digital transformation journey, harnessing the Doxis platform to streamline document processing and content management needs. We look forward to partnering with Carlyle and SER to accelerate international expansion, invest in AI innovation and enhance the Company’s product offering.”
“We are immensely proud to have partnered with SER during such a significant period of growth and transformation for the business,” said Dr. Thorsten Dippel, Managing Director in the Carlyle Europe Technology Partners (“CETP”) Investment Advisory team. “Through our work with Dr. John Bates and his incredible team, the Company has developed into the category-leading, international ICA software vendor it is today. SER is well-placed to continue its success story as an enterprise software player of scale in the large and growing global ECM market. We are delighted to partner with TA as the new lead investor in SER as the Company enters the next phase of its growth journey.”
The transaction is subject to customary regulatory approvals.
About SER
Trusted by over 5 million users worldwide, SER is defining Intelligent Content Automation (ICA), the next generation of Enterprise Content Management which leverages AI to provide intelligent content understanding and process automation. SER’s highly scalable Doxis platform brings ICA capabilities into a single, unified platform that works seamlessly across multiple applications and vendor ecosystems, such as SAP, Salesforce and Microsoft. Offering many pre-built solutions and user-friendly no-code tooling, SER’s Doxis delivers rapid time-to-value, superior ROI and lower total cost of ownership for next-generation content applications. Headquartered in Bonn, Germany, SER has a well-established market leadership position in DACH and a fast-growing international business with blue-chip customers around the world.
About TA
TA is a leading global private equity firm focused on scaling growth in profitable companies. Since 1968, TA has invested in more than 560 companies across its five target industries – technology, healthcare, financial services, consumer and business services. Leveraging its deep industry expertise and strategic resources, TA collaborates with management teams worldwide to help high-quality companies deliver lasting value. The firm has raised $65 billion in capital to date and has over 150 investment professionals across offices in Boston, Menlo Park, Austin, London, Mumbai and Hong Kong. More information about TA can be found at www.ta.com.
About Carlyle
Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across its business and conducts its operations through three business segments: Global Private Equity, Global Credit and Global Investment Solutions. With $426 billion of assets under management as of December 31, 2023, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies and the communities in which we live and invest. Carlyle employs more than 2,200 people in 28 offices across four continents. Further information is available at www.carlyle.com. For more, follow Carlyle on LinkedIn and X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240321414321/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press release
Ranks 125th Among 500 Companies Around the GlobeTop 10% in the Environmental Sector Among 3,000 Major Global Companies Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 10
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release
Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom